First case report of transformation of adenocarcinoma to adenosquamous carcinoma with giant-cell carcinoma harboring HER2 mutation after zongertinib (BI 1810631) resistance.

Abstract excerpt

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) mutations have been identified as a rare molecular subset in non-small cell lung cancer (NSCLC) with poor prognosis and limited treatment options. Zongertinib, an irreversible covalent HER2 inhibitor, demonstrated promising response rates and safety profile in the Beamion LUNG-1 trial, leading to approval for previously treated HER2-mutant NSCLC....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acrylamides
• Share to Adenocarcinoma